Dr. Reddys Laboratories is currently trading at Rs. 4839.65, up by 10.05 points or 0.21% from its previous closing of Rs. 4829.60 on the BSE.
The scrip opened at Rs. 4861.15 and has touched a high and low of Rs. 4868.00 and Rs. 4820.05 respectively. So far 6001 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5514.65 on 21-Sep-2020 and a 52 week low of Rs. 2497.60 on 19-Mar-2020.
Last one week high and low of the scrip stood at Rs. 5018.70 and Rs. 4673.90 respectively. The current market cap of the company is Rs. 80309.00 crore.
The promoters holding in the company stood at 26.74%, while Institutions and Non-Institutions held 43.50% and 15.66% respectively.
Dr. Reddy’s Laboratories has entered into a definitive agreement with Glenmark Pharmaceuticals to acquire, subject to completion of certain precedent actions and closing activities, brands Momat Rino (for Russia, Kazakhstan and Uzbekistan), Momat Rino Advance (for Russia), Momat A (for Kazakhstan and Uzbekistan), Glenspray and Glenspray Active (for Ukraine), along-with rights to the trademarks, dossiers and patents for the territories mentioned.
The acquired brands represent two types of products i.e mometasone mono product and combination of mometasone with azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
Watch our Stock Market Target Calls Quality, Track sheet – Click Here or Subscribe us for Stock Market Trading >>>> Stock Cash Tips
No comments:
Post a Comment